Methylphenidate sustained release - DURECT Corporation

Drug Profile

Methylphenidate sustained release - DURECT Corporation

Alternative Names: Methydur sustained release capsules; ORADUR-ADHD; ORADUR-Methylphenidate; ORADUR®-Methylphenidate ER

Latest Information Update: 21 Sep 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator DURECT Corporation
  • Developer DURECT Corporation; Orient Pharma
  • Class Behavioural disorder therapies; Neuroprotectants; Phenylacetates; Piperidines; Sleep disorder therapies; Small molecules
  • Mechanism of Action Adrenergic receptor modulators; Central nervous system stimulants; Dopamine release stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Attention-deficit hyperactivity disorder; Attention-deficit hyperactivity disorder

Highest Development Phases

  • Registered Attention-deficit hyperactivity disorder

Most Recent Events

  • 18 Sep 2018 Methylphenidate sustained release - DURECT Corporation is available for licensing in Asia, Pacific Rim countries (excluding Europe, Japan, North America) as of 18 Sep 2018. http://www.oppharma.com/index.php/eng/index
  • 18 Sep 2018 Registered for Attention-deficit hyperactivity disorder (In adolescents, In children) in Taiwan (PO) - First Global Approval
  • 18 Sep 2018 Orient Pharma intends to launch ORADUR-methylphenidate extended-release capsule for Attention deficit hyperactivity disorder in Taiwan in 2019
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top